Pulmonary Nodules and Lung Cancer
Conditions
Interventions
Pure solid density group (study group):None
Ground-glass opacity group (control group):None
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. In the bidirectional cohort of this study, the retrospective research patient enrollment period is from January 1, 2023, to September 30, 2024, and the prospective research patient enrollment period is from the launch of the project to December 31, 2027; 2. Age >=18 years old; 3. Gender: No gender restrictions; 4. Inclusion of patients confirmed to have pulmonary opacities and diagnosed benign and malignant pulmonary nodules, and mass lung cancer patients through chest CT examination; (1) Lung cancer: Confirmed as primary lung cancer through lesion tissue and/or cytopathological diagnosis; Disease staging is verified according to the International Lung Cancer TNM Staging (9th Edition) criteria; (2) Benign diseases: Benign diseases confirmed by pathological diagnosis, complete absorption of the lesion within a 2-year follow-up period, and stability of solid pulmonary nodules within 2 years, and confirmed by in-hospital multidisciplinary expert team discussion when necessary. 5. For patients assessed by doctors as having a high risk of malignancy, or for patients who voluntarily wish to further dynamically monitor the risk of disease, they are included in the blood collection group for further risk assessment. Lung cancer.
Exclusion criteria
Exclusion criteria: 1. Patient's age is less than 18 years old; 2. In prospective studies, patients without chest CT imaging from the participating unit's hospital or those who refuse to sign the informed consent form; 3. In retrospective studies, patients with severe loss of clinical data, or without chest CT imaging from the participating unit's hospital; 4. Patients who have peripheral blood drawn and have other systemic tumors, severe basic diseases of other organs, immune system deficiencies, or connective tissue diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinically relevant information characteristics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imaging;Pathology/Molecular Pathology;Treatment method;Survival prognosis; | — |
Countries
China
Contacts
Public ContactYang Li
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed